


In the Claims:

1. (Previously Presented): A pharmaceutical composition comprising (-)- β -L-Dioxolane-Cytidine or a pharmaceutically acceptable salt thereof ~~at least one active~~ compound of formula (I):



(I)

~~or a pharmaceutically acceptable salt thereof,~~

~~wherein~~

~~B is cytosine, and~~

~~R is H; and~~

the Bcr-Abl tyrosine kinase inhibitor imatinib mesylate,

wherein (-)- β -L-Dioxolane-Cytidine or pharmaceutically acceptable salt thereof ~~said~~ compound of formula (I) ~~or a pharmaceutically acceptable salt thereof~~ and said Bcr-Abl tyrosine kinase inhibitor are present in a ratio of 1:5 to 1:2.

2. (Cancelled);

3. (Cancelled);

4. (Cancelled);

5. (Cancelled);

6. (Cancelled);

7. (Cancelled);

8. (Cancelled);

9. (Cancelled);

10. (Cancelled);


11. (Cancelled);

12. (Cancelled);

13. (Cancelled);

14. (Cancelled);

15. (Currently Amended): A method of treating a patient having leukemia comprising administering to said patient a therapeutically effective amount of (-)- β -L-Dioxolane-Cytidine or a pharmaceutically acceptable salt thereof ~~a compound of formula I:~~



~~or a pharmaceutically acceptable salt thereof,~~

~~wherein~~

~~B is cytosine, and~~

~~R is H; and~~

administering to said patient a therapeutically effective amount of the Bcr-Abl tyrosine kinase inhibitor imatinib mesylate,

wherein said (-)- β -L-Dioxolane-Cytidine or pharmaceutically acceptable salt thereof compound of formula (I) ~~or a pharmaceutically acceptable salt thereof~~ and said Bcr-Abl tyrosine kinase inhibitor are administered at a ratio of 1:5 to 1:2.

16. (Cancelled);

17. (Previously Presented): The method according to claim 15, wherein said patient is suffering from acute myelogenous leukemia.

18. (Previously Presented): The method according to claim 15, wherein said patient is suffering from chronic myelogenous leukemia in blastic phase.

19. (Previously Presented): The method according to claim 15, wherein said patient has refractory/relapsed leukemia.

20. (Previously Presented): The method according to claim 15, wherein said patient has refractory / relapsed leukemia and said patient has been previously treated with imatinib mesylate.

21. (Previously Presented): The method according to claim 15, wherein said patient has refractory/relapsed leukemia, said patient has been previously treated with imatinib mesylate, and said patient is resistant to imatinib mesylate.

22. (Cancelled):

23. (Cancelled):

24. (Cancelled):

25. (Previously Presented): A pharmaceutical composition according to claim 1, further comprising at least one pharmaceutically acceptable carrier or excipient.

26. (Previously Presented): A method according to claim 15, wherein said patient is suffering from chronic myelogenous leukemia.

27. (Previously Presented): A method according to claim 15, wherein said patient is suffering from acute lymphocytic leukemia.

28. (Previously Presented): A method according to claim 15, wherein said patient is suffering from chronic lymphocytic leukemia.

29. (Previously Presented): A method according to claim 15, wherein said patient is suffering from hairy cell leukemia.

30. (Previously Presented): A method according to claim 15, wherein said patient is suffering from acute myelogenous leukemia, acute myeloid leukemia, chronic myelogenous leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia, acute lymphocytic

leukemia, hairy cell leukemia, myelodysplastic syndrome or chronic myelogenous leukemia in blastic.

31. (Currently Amended): A pharmaceutical composition according to claim 1, wherein said ~~(-)-β-L-Dioxolane-Cytidine compound of formula (I)~~ or [[a]] pharmaceutically acceptable salt thereof is at least 95% free of the corresponding (+) enantiomer.

32. (Currently Amended): A pharmaceutical composition according to claim 1, wherein said ~~(-)-β-L-Dioxolane-Cytidine compound of formula (I)~~ or [[a]] pharmaceutically acceptable salt thereof is at least 99% free of the corresponding (+) enantiomer.

33. (Cancelled);

34. (Cancelled);

35. (Cancelled);

36. (Cancelled);

37. (Cancelled);

38. (Cancelled);

39. (Currently Amended): A method according to claim 15, wherein said ~~(-)-β-L-Dioxolane-Cytidine compound of formula (I)~~ or [[a]] pharmaceutically acceptable salt thereof is administered to said patient at a dose between 1 mg/m² and 8 mg/m², and said Bcr-Abl tyrosine kinase inhibitor is administered to said patient at a dose between 0.1 gm/m² and 30 gm/m².

40. (Currently Amended): A method according to claim 15, wherein said ~~(-)-β-L-Dioxolane-Cytidine compound of formula (I)~~ or [[a]] pharmaceutically acceptable salt thereof is administered to said patient at a dose between about 1 mg/m² and about 8 mg/m², and said Bcr-Abl tyrosine kinase inhibitor is administered to said patient at a dose between 0.1 gm/m² and 6

gm/m².

41. (Currently Amended): A method according to claim 15, wherein said ~~(-)-β-L-Dioxolane-Cytidine compound of formula (I)~~ or [[a]] pharmaceutically acceptable salt thereof and said Bcr-Abl tyrosine kinase inhibitor are administered sequentially.

42. (Currently Amended): A method according to claim 15, wherein said ~~(-)-β-L-Dioxolane-Cytidine compound of formula (I)~~ or [[a]] pharmaceutically acceptable salt thereof and said Bcr-Abl tyrosine kinase inhibitor are administered simultaneously in separate pharmaceutical formulations.

43. (Currently Amended): A method according to claim 15, wherein said ~~(-)-β-L-Dioxolane-Cytidine compound of formula (I)~~ or [[a]] pharmaceutically acceptable salt thereof and said Bcr-Abl tyrosine kinase inhibitor are administered simultaneously in a combined pharmaceutical formulation.

44. (Cancelled);

45. (Cancelled);

46. (Cancelled);

47. (Cancelled);

48. (Cancelled);

49. (Cancelled);

50. (Cancelled);

51. (Cancelled);

52. (Cancelled);

53. Cancelled

54. Cancelled

55. Cancelled

56. Cancelled

57. Cancelled

58. Cancelled

59. Cancelled

60. Cancelled

61. Cancelled

62. Cancelled

63. (Currently Amended): A method according to claim 15 ~~52~~, wherein said ~~(-)-β-L-Dioxolane-Cytidine β-L-OrbC~~ is administered at 6mg/m^2 over 30 minutes per day on days 1 to 5 and imatinib mesylate is administered at 1gm/m^2 over 2 hours daily on days 1 to 5.

64. (Currently Amended): A method according to claim 15 ~~52~~, wherein said (-)-β-L-Dioxolane-Cytidine β-L-OrbC is administered at 5mg/m^2 over 30 minutes per day on days 1 to 5 and imatinib mesylate is administered at 12gm/m^2 over 2 hours daily on days 1 to 3.